Tag Archives: biomarkers for immune-oncology therapies

QIAGEN receives worldwide license from The Johns Hopkins University for biomarkers for immune-oncology therapies in cancer treatment

Option to add new biomarkers for microsatellite instability (MSI) and mismatch repair (MMR) to QIAGEN’ s NGS panels Hilden, Germany, and Germantown, Maryland, 07-Jun-2017 — /EuropaWire/ — QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced it has received a worldwide … Read the full press release